Careteq Ltd. · ASX:CTQ
Careteq — H1 FY2025 Earnings Presentation
16 slides from Careteq's earnings presentation, February 2025
Slide 1: FY25 Interim Results
FY25 INTERIM RESULTS Maiden EBITDA profit achieved ahead of target February 2025
Slide 2: Disclaimer and Important Notices
Disclaimer and Important Notices 1H FY25 Results Presentation | 2
Slide 3: Highlights H1 FY25 vs. H1 FY24
Highlights H1 FY25 vs. H1 FY241 H1 Revenue and EBITDA Revenue EBITDA 4.5 4 $4.0m $0.9m 4 3.47 3.5 Income +15.5% on pcp EHS EBITDA2, tracking ahead 3 of FY24 results - continued 2.5 growth expected for FY25 2 1.5 $0.2m $0.15m 1 0.5 0.24 Group EBITDA including one- Statutory net loss vs. $1.0m off cos
Slide 4: 1H FY25 Operational highlights
Streamlined Focus on Medication Integration of Embedded Health Management Solutions (EHS) 1H FY25 The Sofihub divestment and full Integration is progressing well, delivering Operational acquisition of EHS have streamlined operational synergies and cost operations, allowing Careteq to focus efficienc
Slide 5: Company overview
Company overview We are Australia’s Medication Management (Aged Care) Medication Management (Home Care) leading medication management business. SERVICES: MARKETPLACE SOFTWARE: N Australia’s largest provider of medication Matching GPs’ Home Medication Review We provide clinical management services an
Slide 6: The problem we solve
The problem we solve Medication misadventure Medication-related harm is a critical issue in healthcare, encompassing adverse drug 1 in 2 88% 66% reactions, medication errors, and complications that jeopardise patient safety and lead to increased healthcare costs. People aged 65+ are Likelihood of an
Slide 7: How we solve it
How we solve it The Medication Our Accredited Pharmacists conduct Medication Management Review Management Reviews to assess a patient's medication process helps to: regimen and ensure it's appropriate and safe: 01. 02. Review patient's medications Evaluate the safety and Reduce the risk of adverse m
Slide 8: Key stakeholders and business model
Patient (has potential medication issue) Key stakeholders and business model Residential Aged Care Facilities Home Care Clients and/or (RMMRs & QUM)1 Providers (HMRs) GPs (refers patient for medication review – Medicare Our value proposition: reimbursement) Reduction in medication- related harm, red
Slide 9: EHS and HMRR Referrals Synergies
EHS and HMRR Referrals Synergies Dedicated and laser focused 01 02 medication management and Integrated medication Expanded reach clinical governance company management platform and service offering Combining EHS’s residential services with EHS’s clinical governance expertise complements HMR Referra
Slide 10: FY25 – strategic pillars and outlook
01 Integrated operating platform on track FY25 – • The single software platform integration is on track for roll out during March this year. • The end result will be a cohesive medication management platform across aged, home, and strategic disability care. pillars and outlook 02 Further synergies t
Slide 11: Appendix
Appendix 1H FY25 Results Presentation | 11
Slide 12: Profit & Loss
Account 31 Dec 2024 31 Dec 2023 VAR (%) Trading Income $Am $Am Profit Total Trading Income 4.00 3.5 +15.5 Other Income & Loss Total Other Income Total Income 0.3 4.3 0.3 3.8 +11.5 +15.1 Less Direct Costs Total Direct Costs (2.3) (1.9) -20.1 Gross Profit from continuing operations 2.0 1.9 +10.0 GP Ma
Slide 13: Balance sheet
Assets Liabilities Current Assets $Am Current Liabilities $Am Balance Cash at Bank 0.85 Trade and Other Payables 1.38 Trade and Other Receivables 1.18 Lease Liabilities 0.07 sheet Inventories 0.00 Financial Liabilities 0.98 Contract Assets 0.75 Employee Benefits 0.43 Income tax 0.51 Other Current As
Slide 14: Cash flow statement
31 Dec 2024 31 Dec 2023 CASH FLOWS FROM OPERATING ACTIVITIES $Am $Am Receipts from customers (inclusive of GST) 4.47 3.96 Cash flow Government grants and tax incentives 0.00 0.03 Payments to suppliers and employees (inclusive of GST) (4.98) (5.20) statement Net cash used in operating activities (0.5
Slide 15: Corporate overview
Corporate BOARD OF DIRECTORS overview CAPITAL STRUCTURE 237m 59.9% MARK SIMARI Executive Chairman BRETT CHEONG Non-Executive Director STEPHEN MUNDAY Non-Executive Director Shares on issue Top 20 ownership Over 16 years’ Board experience in Over 40 years of background Over 40 years business experienc
Slide 16: Thank You
Thank You MARK SIMARI CORPORATE ADDRESS Executive Chairman CARETEQ, Level 10, 99 Queen Street mark.simari@careteq.com.au Melbourne, 3000 1H FY25 Results Presentation | 16